Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plus Therapeutics (PSTV) Gains from Investment Securities (2016 - 2025)

Plus Therapeutics (PSTV) has disclosed Gains from Investment Securities for 16 consecutive years, with $125814.0 as the latest value for Q3 2025.

  • On a quarterly basis, Gains from Investment Securities fell 78.98% to $125814.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $125814.0, a 78.98% decrease, with the full-year FY2024 number at $598540.0, up 327.2% from a year prior.
  • Gains from Investment Securities was $125814.0 for Q3 2025 at Plus Therapeutics, up from $75356.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $598540.0 in Q3 2024 to a low of -$4.7 million in Q2 2024.
  • A 5-year average of -$186471.6 and a median of $22781.5 in 2022 define the central range for Gains from Investment Securities.
  • Peak YoY movement for Gains from Investment Securities: crashed 3750.59% in 2024, then soared 3668800.0% in 2025.
  • Plus Therapeutics' Gains from Investment Securities stood at $3000.0 in 2021, then surged by 2511.13% to $78334.0 in 2022, then plummeted by 92.75% to $5679.0 in 2023, then skyrocketed by 10439.53% to $598540.0 in 2024, then tumbled by 78.98% to $125814.0 in 2025.
  • Per Business Quant, the three most recent readings for PSTV's Gains from Investment Securities are $125814.0 (Q3 2025), $75356.0 (Q2 2025), and $36689.0 (Q1 2025).